IMVT
Immunovant, Inc.$30.86-2.01 (-6.12%)Prev Close$32.86·MCap$6.75B·P/E—·Vol537.9K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
25
$11.22M
◆
Net Activity
Net Seller
$11.22M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Immunovant, Inc. (IMVT) has been exclusively selling, with 0 insider purchases totaling $0.00 and 25 insider sales totaling $11.22M. The most recent insider transaction was by Fromkin Andrew J. (director), who sold $7.44M worth of shares on May 29, 2026. Immunovant, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $6.75B.
IMVT Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | Fromkin Andrew J. | director | Sell | 221,951 | $33.51 | $7.44M | 284,850-44% |
| May 22, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,115 | $32.45 | $101.1K | 244,973 |
| May 20, 2026 | Pande Atul | director | Sell | 6,000 | $32.00 | $192.0K | 116,731 |
| May 1, 2026 | Susman Robert Graham | director | Sell | 2,502 | $27.17 | $68.0K | 36,394 |
| Apr 24, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K | 251,685 |
| Apr 24, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K | 247,596 |
| Apr 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 10,132 | $24.83 | $251.6K | 255,957 |
| Apr 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 5,165 | $24.83 | $128.2K | 183,231 |
| Apr 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 8,722 | $24.83 | $216.6K | 245,222 |
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
| Jan 17, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,298 | $23.83 | $54.8K | 324,875 |
| Jan 17, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,383 | $23.83 | $56.8K | 359,908 |
| Jan 17, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,767 | $23.83 | $208.9K | 964,640 |
| Jan 15, 2025 | Roivant Sciences Ltd. | Buy | 16,845,010 | $20.00 | $336.90M8.3% OS | 96,650,344 | |
| Jan 10, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,105 | $24.10 | $98.9K | 327,064 |
| Jan 10, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 5,105 | $24.10 | $123.0K | 972,992 |
| Dec 4, 2024 | Hughes Douglas J. | Director | Sell | 5,425 | $28.54 | $154.8K | 119,585 |
| Dec 4, 2024 | Pande Atul | Director | Sell | 7,750 | $28.54 | $221.2K | 86,663 |
| Nov 22, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,174 | $25.45 | $106.2K | 331,169 |
| Nov 22, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 3,650 | $25.45 | $92.9K | 319,228 |
| Nov 22, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,353 | $25.45 | $85.3K | 361,791 |
Showing 1–50 of 171
1 / 4
IMVT Insider Buying Activity
The following table shows recent insider purchases of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 15, 2025 | Roivant Sciences Ltd. | Buy | 16,845,010 | $20.00 | $336.90M8.3% OS | 96,650,344 |
IMVT Insider Selling Activity
The following table shows recent insider sales of Immunovant, Inc. (IMVT) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | Fromkin Andrew J. | director | Sell | 221,951 | $33.51 | $7.44M | 284,850-44% |
| May 22, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,115 | $32.45 | $101.1K | 244,973 |
| May 20, 2026 | Pande Atul | director | Sell | 6,000 | $32.00 | $192.0K | 116,731 |
| May 1, 2026 | Susman Robert Graham | director | Sell | 2,502 | $27.17 | $68.0K | 36,394 |
| Apr 24, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 2,754 | $29.62 | $81.6K | 251,685 |
| Apr 24, 2026 | Girao Tiago | officer: Chief Financial Officer | Sell | 25,760 | $29.62 | $763.0K | 247,596 |
| Apr 10, 2026 | Stout Jay S | officer: Chief Technology Officer | Sell | 10,132 | $24.83 | $251.6K | 255,957 |
| Apr 10, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 5,165 | $24.83 | $128.2K | 183,231 |
| Apr 10, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 8,722 | $24.83 | $216.6K | 245,222 |
| Mar 20, 2026 | Van Tuyl Christopher | officer: Chief Legal Officer | Sell | 2,877 | $24.97 | $71.8K | 147,053 |
| Feb 27, 2026 | Gloria Melanie | officer: Chief Operating Officer | Sell | 3,238 | $27.85 | $90.2K | 172,074 |
| Jan 21, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,977 | $26.03 | $51.5K | 0 |
| Jan 7, 2026 | Stout Jay S | Chief Technology Officer | Sell | 1,203 | $26.53 | $31.9K | 0 |
| Dec 18, 2025 | Van Tuyl Christopher | Chief Legal Officer | Sell | 10,813 | $26.91 | $290.9K | 0 |
| Dec 1, 2025 | Fromkin Andrew J. | Director | Sell | 22,249 | $23.25 | $517.2K | 0 |
| Dec 1, 2025 | Hughes Douglas J. | Director | Sell | 15,000 | $23.24 | $348.7K | 0 |
| Nov 20, 2025 | Gloria Melanie | Chief Operating Officer | Sell | 12,626 | $23.62 | $298.2K | 0 |
| Oct 22, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,595 | $19.03 | $49.4K | 0 |
| Oct 22, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,520 | $19.03 | $48.0K | 0 |
| Oct 8, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,272 | $16.30 | $20.7K | 0 |
| Oct 8, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,585 | $16.30 | $25.8K | 0 |
| Jul 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,385 | $18.15 | $43.3K | 0 |
| Jul 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,805 | $18.15 | $50.9K | 0 |
| Jul 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 1,160 | $17.24 | $20.0K | 0 |
| Jul 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,519 | $17.24 | $26.2K | 0 |
| Apr 23, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,349 | $14.79 | $34.7K | 0 |
| Apr 23, 2025 | Stout Jay S | Chief Technology Officer | Sell | 1,925 | $14.79 | $28.5K | 0 |
| Apr 16, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,993 | $14.89 | $44.6K | 0 |
| Apr 16, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,321 | $14.89 | $123.9K | 0 |
| Apr 9, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 11,063 | $12.99 | $143.7K | 0 |
| Apr 9, 2025 | Geffner Michael | Chief Medical Officer | Sell | 6,169 | $12.99 | $80.1K | 0 |
| Apr 9, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 28,094 | $12.99 | $364.9K | 0 |
| Apr 9, 2025 | Stout Jay S | Chief Technology Officer | Sell | 5,004 | $12.99 | $65.0K | 0 |
| Mar 7, 2025 | Fromkin Andrew J. | Director | Sell | 8,000 | $19.60 | $156.8K | 0 |
| Feb 21, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,814 | $20.86 | $58.7K | 321,952 |
| Feb 21, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,055 | $20.86 | $42.9K | 357,353 |
| Feb 21, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 15,439 | $20.86 | $322.1K | 948,786 |
| Jan 24, 2025 | Geffner Michael | Chief Medical Officer | Sell | 2,657 | $23.59 | $62.7K | 132,314 |
| Jan 24, 2025 | Stout Jay S | Chief Technology Officer | Sell | 2,195 | $23.59 | $51.8K | 139,991 |
| Jan 17, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 2,298 | $23.83 | $54.8K | 324,875 |
| Jan 17, 2025 | Macias William L. | Chief Medical Officer | Sell | 2,383 | $23.83 | $56.8K | 359,908 |
| Jan 17, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 8,767 | $23.83 | $208.9K | 964,640 |
| Jan 10, 2025 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,105 | $24.10 | $98.9K | 327,064 |
| Jan 10, 2025 | Salzmann Peter | Chief Executive Officer | Sell | 5,105 | $24.10 | $123.0K | 972,992 |
| Dec 4, 2024 | Hughes Douglas J. | Director | Sell | 5,425 | $28.54 | $154.8K | 119,585 |
| Dec 4, 2024 | Pande Atul | Director | Sell | 7,750 | $28.54 | $221.2K | 86,663 |
| Nov 22, 2024 | Barnett Eva Renee | Chief Financial Officer | Sell | 4,174 | $25.45 | $106.2K | 331,169 |
| Nov 22, 2024 | Levine Mark S. | Chief Legal Officer | Sell | 3,650 | $25.45 | $92.9K | 319,228 |
| Nov 22, 2024 | Macias William L. | Chief Medical Officer | Sell | 3,353 | $25.45 | $85.3K | 361,791 |
IMVT Insiders
Similar Stocks to IMVT
VRTX
Vertex Pharmaceuticals Incorporated
$425.57-2.91%
$113.59B
REGN
Regeneron Pharmaceuticals, Inc.
$593.91-1.06%
$63.34B
ALNY
Alnylam Pharmaceuticals, Inc.
$285.63-3.44%
$40.32B
RVMD
Revolution Medicines, Inc.
$152.51-6.84%
$33.48B
UTHR
United Therapeutics Corporation
$535.88-1.63%
$23.64B
INSM
Insmed Incorporated
$100.82-4.89%
$23.17B
INCY
Incyte Corporation
$93.67-2.04%
$19.33B
MRNA
Moderna, Inc.
$44.74-2.87%
$18.72B